Newsfile Corp
26 May 2026, 11:40 UTC · 2h ago
Source · https://www.newsfilecorp.com/release/298851/OS-Therapies-to-Attend-Upcoming-Medical-Financial-and-Industry-Conferences
Read source
Search tags
Story key points
5 claims · impact-rated
OS Therapies expects to submit a Biologics License Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2026. — A BLA submission is the final regulatory hurdle for commercialization and a primary catalyst for biotech valuation.
+0.80The company anticipates receiving Conditional Marketing Authorisations from the UK's MHRA and the EMA for OST-HER2 in 2026. — Expansion into European and UK markets significantly increases the addressable market and revenue potential.
+0.60OS Therapies expects data readout from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half of 2026. — Clinical data readouts for new indications provide critical evidence of the pipeline's breadth beyond its lead asset.
+0.50The company expects its current cash runway to extend into 2027. — Cash runway provides a baseline of stability and reduces immediate concerns over dilutive financing.
+0.30OS Therapies will attend several upcoming medical, financial, and scientific conferences. — Conference attendance is routine promotional activity and generally does not move markets unless new data is presented.
+0.00Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company reported positive Phase 2b clinical trial data and has multiple upcoming FDA and EMA regulatory milestones in 2026.
No ticker relationship head found.
